ストックスクリーナーアプリを入手
2.05
1.44%
-0.03
前日終値:
$2.08
開ける：
$2.06
24時間の取引高:
615.60K
Relative Volume:
0.43
時価総額：
$78.85M
収益：
$210.70K
当期純損益:
$-21.37M
株価収益率:
-1.8636
EPS:
-1.1
ネットキャッシュフロー:
$-21.10M
1週間 パフォーマンス:
+13.26%
1か月 パフォーマンス:
-33.44%
6か月 パフォーマンス:
+22.02%
1年 パフォーマンス:
-8.07%
1日の値動き範囲:
$2.02
$2.14
1週間の範囲:
$1.75
$2.14
52週間の値動き範囲:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
GANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.05 | 80.00M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
Bond Watch: Will Atlantica Sustainable Infrastructure plc stock benefit from M AMarket Growth Review & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Final Week: Should I average down on Gain Therapeutics Inc stockNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Gain Therapeutics Inc. stock attract ESG capital inflowsVolatility Adjusted Trading & Free Stay Informed With Forecasts - bollywoodhelpline.com
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6% - MarketBeat
Aug PreEarnings: Can Gain Therapeutics Inc continue delivering strong returnsJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Exit Recap: Is Gain Therapeutics Inc attractive for institutional investors2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Wall Street Recap: Is Gain Therapeutics Inc trading at a discountWeekly Earnings Recap & Consistent Profit Trading Strategies - baoquankhu1.vn
Pullback Watch: What is Gain Therapeutics Incs 5 year growth outlookTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Movement Recap: Can Gain Therapeutics Inc outperform in the next rallyJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Fed Impact: Whats the beta of Gain Therapeutics Inc stockMarket Activity Recap & Fast Entry and Exit Trade Plans - baoquankhu1.vn
EPS Watch: Whats the beta of Gain Therapeutics Inc stock2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Aug Intraday: What is Gain Therapeutics Incs TAM Total Addressable MarketJuly 2025 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Why Gain Therapeutics Inc. stock could see breakout soonQuarterly Risk Review & Free Technical Pattern Based Buy Signals - Улправда
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop - Defense World
Reviewing Aldeyra Therapeutics (NASDAQ:ALDX) & Gain Therapeutics (NASDAQ:GANX) - Defense World
How Ideal Power Inc. (5ILA) stock gains from tech spendingJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Улправда
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Is Gain Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Momentum & Low Risk Growth Stock Ideas - Улправда
Why Gain Therapeutics Inc. stock attracts high net worth investorsDollar Strength & Risk Controlled Daily Plans - Улправда
Published on: 2026-01-09 02:02:08 - Улправда
Stock Recap: Why Gain Therapeutics Inc. stock attracts high net worth investorsEarnings Overview Summary & Verified Momentum Stock Watchlist - Улправда
Can Gain Therapeutics Inc. stock reach $100 price target2025 Earnings Surprises & Daily Profit Maximizing Tips - Улправда
Gain Therapeutics provides additional data from Phase 1b study of GT-02287 - MSN
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Nigeria
Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - The Manila Times
Biotech firm Gain Therapeutics lines up three events in San Francisco - Stock Titan
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare ... - heraldandnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker - Investing.com
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat
Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World
GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data - Parkinson's News Today
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Canada
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa
Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase - StocksToTrade
Is Gain Therapeutics Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75 - Nasdaq
Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
US Market Wrap: Why Gain Therapeutics Inc. stock could see breakout soonJuly 2025 Retail & Weekly High Return Forecasts - Улправда
Can Gain Therapeutics Inc. stock sustain institutional interestJuly 2025 News Drivers & Community Consensus Stock Picks - Улправда
GANX - Finviz
Can Gain Therapeutics Inc. stock weather global recession2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Улправда
Earnings Recap: Is Gain Therapeutics Inc. stock a smart buy before Fed meetingWeekly Loss Report & Growth Focused Stock Reports - Улправда
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
2.92%
2.36%
大文字化:
|
ボリューム (24 時間):